CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02637531
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:43.923526+00:00
Published At: 2022-04-04T00:00:00+00:00
Record Updated At: 2022-04-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Solid Tumors (Part A/B/C/D)", "Non-small Cell Lung Cancer (Part E)", "Melanoma (Part E)", "Squamous Cell Cancer of the Head and Neck (Part E)", "Triple Negative Breast Cancer (Part F)", "Adrenocortical Carcinoma (Part G)", "Mesothelioma (Part G)", "High-circulating Myeloid-derived Suppressor Cells (Part H)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-04-04"
protocolSection.identificationModule.nctId: "NCT02637531"
protocolSection.identificationModule.officialTitle: "A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.